Clint Cooksey
Payments from drug & device makers
Across 308 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$670
- AbbVie$634
- Novo Nordisk$595
- AstraZeneca$456
- GSK$411
- Amgen$366
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,747100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 47 | $670 |
| AbbVie | 43 | $634 |
| Novo Nordisk | 40 | $595 |
| AstraZeneca | 23 | $456 |
| GSK | 26 | $411 |
| Amgen | 25 | $366 |
| Pfizer | 18 | $267 |
| Abbott | 10 | $169 |
| Axsome Therapeutics, Inc. | 9 | $160 |
| Otsuka America Pharmaceutical, Inc. | 8 | $139 |
| Bayer | 7 | $131 |
| Teva Pharmaceuticals USA, Inc. | 10 | $129 |
| Astellas Pharma US Inc | 6 | $92 |
| Merck | 5 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $59 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $50 |
| Boehringer Ingelheim | 4 | $50 |
| Lundbeck LLC | 3 | $44 |
| Biohaven Pharmaceuticals, Inc. | 3 | $37 |
| Exact Sciences | 2 | $36 |
| Novartis | 2 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Corium, LLC | 1 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $25 |
| Amarin Pharma, Inc. | 1 | $15 |
| Intuitive Surgical | 1 | $13 |
| Genentech USA, Inc. | 1 | $9 |
How this compares
$4,747 in reported general payments places this provider in the 90th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 123 | $155,165 |
| OzempicSemaglutide | 67 | $73,111 |
| JardianceEmpagliflozin | 76 | $66,290 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $55,726 |
| EliquisApixaban | 61 | $45,873 |
| FarxigaDapagliflozin Propanediol | 47 | $34,902 |
| TrulicityDulaglutide | 33 | $31,433 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $29,771 |
| LinzessLinaclotide | 32 | $25,933 |
| MyrbetriqMirabegron | 41 | $25,319 |
| KerendiaFinerenone | 28 | $24,332 |
| RybelsusSemaglutide | 13 | $22,111 |
| XareltoRivaroxaban | 29 | $19,316 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $17,652 |
| JanuviaSitagliptin Phosphate | 23 | $13,745 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $670 | $186,597156 claims |
| Novo NordiskOzempic, Rybelsus | $595 | $95,22380 claims |
| Boehringer IngelheimJardiance | $50 | $66,29076 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $411 | $60,33082 claims |
| PfizerEliquis, Premarin | $267 | $48,34473 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $456 | $43,46360 claims |
| AbbVieLinzess | $634 | $25,93332 claims |
| Astellas Pharma US IncMyrbetriq | $92 | $25,31941 claims |
| BayerKerendia | $131 | $24,33228 claims |
| MerckJanuvia | $66 | $13,74523 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $59 | $9,67517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,610 family providers in Louisiana.
Other family in Jena
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.